ONX-0914 (PR-957)

For research use only. Not for use in humans.

目录号:S7172

ONX-0914 (PR-957) Chemical Structure

CAS No. 960374-59-8

ONX-0914 (PR-957)是一种有效的,选择性immunoproteasome抑制剂,无细胞试验中对组成型蛋白酶体具有最低的交叉反应性。

规格 价格 库存 购买数量  
RMB 2367.48 现货
RMB 7100.88 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的ONX-0914 (PR-957)发表文献14篇:

客户使用该产品的2个实验数据:

  • Dependence of SPRI signal on receptor concentration: (a) ONX 0914 inhibitor, (b) inhibitor 5. 20Si concentration: 2.8 μg/mL, pH 7.4

    Cell Mol Bioeng, 2017, 10(2):174-185. ONX-0914 (PR-957) purchased from Selleck.

  • Mice were treated with daily doses of 10 mg/kg ONX-0914 iv or vehicle (n = 5–6). Not significant by log-rank test.

    Parasite Immunol, 2015, 37(11):599-604.. ONX-0914 (PR-957) purchased from Selleck.

产品安全说明书

Proteasome抑制剂选择性比较

生物活性

产品描述 ONX-0914 (PR-957)是一种有效的,选择性immunoproteasome抑制剂,无细胞试验中对组成型蛋白酶体具有最低的交叉反应性。
特性 ONX-0914 是第一个高度选择性,小分子,免疫蛋白酶抑制剂。
靶点
LMP7 [1]
(Cell-free assay)
~10 nM
体外研究

ONX-0914作用于LMP7比作用于下一个最敏感的位点β5或LMP2选择性高20到40倍。ONX-0914在体外和体内抑制LMP7特异性的,MHC-I限制性的抗原,对组成型蛋白酶体具有最低的交叉反应性。ONX-0914选择性抑制LMP7,通过该活化的单核细胞和T细胞产生的干扰素-γ和IL-2,而导致白细胞介素-23(IL-23)的产生受抑制。LMP7受抑制导致90% IL-23的产生受抑制,及50%肿瘤坏死因子-α(TNF-α)和IL-6受抑制。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Raji NVXiOJQxTnWwY4Tpc44h[XO|YYm= NGL3VnVKdmirYnn0bY9vKG:oIIDyc5Rm[XOxbXWgd5VjfW6rdDDi[ZRiNTWrIHnuJIh2dWGwIGLhbokh[2WubIOgeZNqdmdiQl;ETXB[NU6FMEC1JIJ6KG[udX;y[ZNk\W62IHTlcpNqfG:vZYTyfUwhUUN3ME2wMlAxPTgQvF2= NXLTSHZCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNFY4PDZpPkK1NFA3PzR4PD;hQi=>
EBC1 MUnBcpRqfHWvb4KgZZN{[Xl? NET5T28yPSCvZz;r[y=> NYDGbmV[PSCmYYnz NFfyWYxCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDFRmMyKGOnbHzzJJhmdm:pcnHmeIVlKGmwIFPEMVEhdnWmZTDtc5V{\SCjc4Pld5Nm\CCjczD0eY1weiC{ZXfy[ZN{cW:wIHH0JFE2KG2pL3vnMEBxdyCzZDDh[I1qdmm|dHXy[YQh\m:{IEWg[IF6eyCxbjDhcoQhOiCmYYnzJI9n\iC3cDD0c{A{OiCmYYnz MlHNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyME[3OFYoRjJ3MEC2O|Q3RC:jPh?=
SJ-GBM2 MlPudWhVWyCjc4PhfS=> MUPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?= NHnwTJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCwOlc1Pid-MkWwNFY4PDZ:L3G+
SK-N-SH NG\DeINyUFSVIHHzd4F6 MVLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?= NX\PbnlQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNFY4PDZpPkK1NFA3PzR4PD;hQi=>
RPMI8226 M3rtemZ2dmO2aX;uJIF{e2G7 M1fEZ2lvcGmkaYTpc44hd2ZicILveIVie2:vZTDzeYJ2dmm2IHLleIEuOWliaX6gbJVu[W5iUmDNTVgzOjZiY3XscJMhfXOrbnegRm9FUVC\LV7DNFAyKGK7IH\seY9z\XOlZX70JIRmdnOrdH;t[ZRzgSxiSVO1NF0xNjN2zszN NGnEWZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCwOlc1Pid-MkWwNFY4PDZ:L3G+
Raji MYTGeY5kfGmxbjDhd5NigQ>? M2H5O2lvcGmkaYTpc44hd2ZicILveIVie2:vZTDzeYJ2dmm2IHLleIEuOWliaX6gbJVu[W5iUnHqbUBk\WyuczD1d4lv\yCET1TJVHkuKGWyb4jvcYlkcW5iYomg[ox2d3Knc3PlcpQh\GWwc3n0c41mfHK7LDDJR|UxRTBwNEdOwG0> M4[3XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEC2O|Q3Lz5{NUCwOlc1PjxxYU6=
Raji Mm[xSpVv[3Srb36gZZN{[Xl? MlnWTY5pcWKrdHnvckBw\iCycn;0[YF{d22nIIP1ZpVvcXRiYnX0ZU0zcSCrbjDoeY1idiCUYXrpJINmdGy|IIXzbY5oKEKRRFnQXU0h\XCxeH;tbYNqdiCkeTDmcJVwemW|Y3XueEBl\W6|aYTvcYV1enluIFnDOVA:OC53Od88US=> MnvLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyME[3OFYoRjJ3MEC2O|Q3RC:jPh?=
RPMI8226 MWPGeY5kfGmxbjDhd5NigQ>? NF3B[phKdmirYnn0bY9vKG:oIIDyc5Rm[XOxbXWgd5VjfW6rdDDi[ZRiNTKrIHnuJIh2dWGwIGLQUWk5OjJ4IHPlcIx{KHW|aX7nJGJQTEmSWT3ldI95d22rY3nuJIJ6KG[udX;y[ZNk\W62IHTlcpNqfG:vZYTyfUwhUUN3ME2wMlU6|ryP NV;EboU2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNFY4PDZpPkK1NFA3PzR4PD;hQi=>
Raji NILTZ4pHfW6ldHnvckBie3OjeR?= NES3O2xKdmirYnn0bY9vKG:oIEKwd{Bxem:2ZXHzc41mKHO3YoXubZQh[mW2YT2yZ{BqdiCqdX3hckBT[WqrIHPlcIx{KHW|aX7nJGJQTEmSWT2g[ZBwgG:vaXPpckBjgSCobIXvdoV{[2WwdDDk[Y5{cXSxbXX0dpktKEmFNUC9NU4y|ryP MmrxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyME[3OFYoRjJ3MEC2O|Q3RC:jPh?=
RPMI8226 NFqydHlHfW6ldHnvckBie3OjeR?= M3;MVWlvcGmkaYTpc44hd2ZiMkDzJJBzd3SnYYPvcYUhe3WkdX7peEBj\XSjLULjJIlvKGi3bXHuJHJRVUl6MkK2JINmdGy|IIXzbY5oKEKRRFnQXU1meG:6b33pZ4lvKGK7IH\seY9z\XOlZX70JIRmdnOrdH;t[ZRzgSxiSVO1NF0yNjIQvF2= NWjJTFhZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNFY4PDZpPkK1NFA3PzR4PD;hQi=>
SK-N-MC M1\5RZFJXFNiYYPzZZk> NEG1WZdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=> MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTN|OUK1Nkc,Ojl|M{myOVI9N2F-
RD NXPTNJg5eUiWUzDhd5NigQ>? NITLc2ZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUlSgZ4VtdHN? NULpfmRGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmzN|kzPTJpPkK5N|M6OjV{PD;hQi=>
MG 63 (6-TG R) MorhdWhVWyCjc4PhfS=> MXfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVUdiNkOgLFYuXEdiUjmgZ4VtdHN? NXe2bGRiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmzN|kzPTJpPkK5N|M6OjV{PD;hQi=>
NCI-H727 MXHDfZRwfG:6aXPpeJkh[XO|YYm= NUW1fm1JPDhiaILz MXPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2kuUDd{NzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZYZ1\XJiNEigbJJ{KGK7IFjv[YNpe3RiM{OzOFIhe3SjaX7pcoch[mG|ZXSgTGNUKGG|c3H5MEBGSzVyPUCuN:69VQ>? NV\3S29rRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmzN|kzPTJpPkK5N|M6OjV{PD;hQi=>
PC3 MnfPR5l1d3SxeHnjbZR6KGG|c3H5 MUW0PEBpenN? MYDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQR|Mh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBJd2WlaIP0JFM{OzR{IIP0ZYlvcW6pIHLhd4VlKEiFUzDhd5NigSxiRVO1NF0xNjN|zszN NFXDeWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUOzPVI2Oid-MkmzN|kzPTJ:L3G+
HuH7 NFfaNHVEgXSxdH;4bYNqfHliYYPzZZk> MXq0PEBpenN? NXHGbVduS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUHWKNzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZYZ1\XJiNEigbJJ{KGK7IFjv[YNpe3RiM{OzOFIhe3SjaX7pcoch[mG|ZXSgTGNUKGG|c3H5MEBGSzVyPUCuN|nPxE1? NHPtVJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUOzPVI2Oid-MkmzN|kzPTJ:L3G+
Caco2 Ml[5R5l1d3SxeHnjbZR6KGG|c3H5 M3rtWlQ5KGi{cx?= MYPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDZYNwOiClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPDhiaILzJIJ6KEixZXPod5QhOzN|NEKgd5RicW6rbnegZoF{\WRiSFPTJIF{e2G7LDDFR|UxRTFwM988US=> NX7zcW5ZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmzN|kzPTJpPkK5N|M6OjV{PD;hQi=>
DAOY MlzQdWhVWyCjc4PhfS=> MoezdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN? NV[zOYRwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CzPFA5PjNpPkOwN|gxQDZ|PD;hQi=>
A673 Mn;udWhVWyCjc4PhfS=> M2D0TpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy| MmS0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB|OEC4OlMoRjNyM{iwPFY{RC:jPh?=
Rh41 MmPJdWhVWyCjc4PhfS=> NIfVNVByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUni0NUBk\Wyucx?= M{WxVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{iwPFY{Lz5|MEO4NFg3OzxxYU6=
A20 Mm\4SpVv[3Srb36gZZN{[Xl? M{HBZmlvcGmkaYTpc44hd2ZiTF3QNkBqdiCvb4Xz[UBCOjBiY3XscJMh[nliRVzJV2EtKEmFNUC9NE4{OjkQvF2= NUnLR5N7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CzPFA5PjNpPkOwN|gxQDZ|PD;hQi=>
A20 NF\qWJFHfW6ldHnvckBie3OjeR?= MYXJcohq[mm2aX;uJI9nKDJyUzDwdo91\W:|b33lJIJmfGFiNTDpckBud3W|ZTDBNlAh[2WubIOgZpkhTUyLU1GsJGlEPTB;MD60NFHPxE1? M1\adlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{iwPFY{Lz5|MEO4NFg3OzxxYU6=
MOLT4 MWHGeY5kfGmxbjDhd5NigQ>? NEe3fmdKdmirYnn0bY9vKG:oIEKwV{Bxem:2ZX;zc41mKGKndHGgOUBqdiCqdX3hckBOV0yWNDDj[YxteyCkeTDFUGlUSSxiSVO1NF0xNjR{Mt88US=> MmmxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB|OEC4OlMoRjNyM{iwPFY{RC:jPh?=
A20 M{Tub2Z2dmO2aX;uJIF{e2G7 NITpcnhKdmirYnn0bY9vKG:oIF3FR2wyKGmwIH3veZNmKEF{MDDj[YxteyCkeTDFUGlUSSxiSVO1NF0xNjZ7Od88US=> M4LqRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{iwPFY{Lz5|MEO4NFg3OzxxYU6=
MOLT4 NUnROVZQTnWwY4Tpc44h[XO|YYm= NEexXlVKdmirYnn0bY9vKG:oIF3FR2wyKGmwIHj1cYFvKE2RTGS0JINmdGy|IHL5JGVNUVODLDDJR|UxRTBwOUCy{txO M3rXS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{iwPFY{Lz5|MEO4NFg3OzxxYU6=
A20 NFfPTpBHfW6ldHnvckBie3OjeR?= MkfJTY5pcWKrdHnvckBw\iB{MGOgdJJwfGWxc3;t[UBj\XSjIEKgbY4hdW:3c3WgRVIxKGOnbHzzJIJ6KEWOSWPBMEBKSzVyPUCuPVE{|ryP NFHJfJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEO4NFg3Oyd-M{CzPFA5PjN:L3G+
MOLT4 MnXxSpVv[3Srb36gZZN{[Xl? NESzZmZKdmirYnn0bY9vKG:oIEKwV{Bxem:2ZX;zc41mKGKndHGgNkBqdiCqdX3hckBOV0yWNDDj[YxteyCkeTDFUGlUSSxiSVO1NF0xNjl{N988US=> NIrVSWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEO4NFg3Oyd-M{CzPFA5PjN:L3G+
PBMC NYjnW4hVTnWwY4Tpc44h[XO|YYm= M1;uZlExOCCwTR?= M{P0XFMhfG9iN{KgbJJ{ NHHObldKdmirYnn0bY9vKG:oIEKwV{Bxem:2ZXHzc41mKGKndHGgOYkhcW5iaIXtZY4hWEKPQzDj[YxteyCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhWFOPQkWg[ZhxemW|c3nvckBifCBzMECgcm0h[W[2ZYKgN{B1dyB5MjDodpMh[nliUmStVGNTKGGwYXz5d4l{ MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTJ6M{KyNkc,OzF{OEOyNlI9N2F-
PBMC NIWxWW5HfW6ldHnvckBie3OjeR?= NWTqZlNiOTByIH7N MUGzJJRwKDd{IHjydy=> M3XjPGlvcGmkaYTpc44hd2ZiMkDTJJBzd3SnYYPvcYUh[mW2YTC1bUBqdiCqdX3hckBRSk2FIHPlcIx{KGG|c3Xzd4VlKGG|IHnu[JVkfGmxbjDv[kBRW02ENjDlfJBz\XO|aX;uJIF1KDFyMDDuUUBi\nSncjCzJJRwKDd{IHjyd{BjgSCUVD3QR3Ih[W6jbInzbZM> NXPzWZhXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GyPFMzOjJpPkOxNlg{OjJ{PD;hQi=>
PBMC NILHe2xHfW6ldHnvckBie3OjeR?= MVmxNFAhdk1? NYq3SndHOyC2bzC3NkBpenN? NGXxeHlKdmirYnn0bY9vKG:oIEKwV{Bxem:2ZXHzc41mKGKndHGgOYkhcW5iaIXtZY4hWEKPQzDj[YxteyCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhWFOPQkeg[ZhxemW|c3nvckBifCBzMECgcm0h[W[2ZYKgN{B1dyB5MjDodpMh[nliUmStVGNTKG2ndHjv[C=> Mme4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzF{OEOyNlIoRjNzMkizNlIzRC:jPh?=

... Click to View More Cell Line Experimental Data

体内研究 ONX-0914处理风湿性关节炎和狼疮小鼠模型,逆转疾病的征兆,并降低细胞浸润,细胞因子产生,及自身抗体水平在良好的耐受剂量。ONX-0914处理小鼠的最大耐受剂量(MTD)为30 mg/kg体重。ONX-0914为LMP7选择性浓度时,抑制60%IFN-g释放,在更高浓度时,抑制90%。ONX-0914还抑制约50%IL-2产生。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

动物实验:[1]
- 合并
  • Animal Models: 胶原抗体诱导型关节炎(CAIA)和胶原诱导型关节炎(CIA)
  • Dosages: 2, 6 或 10 mg/kg
  • Administration: 静脉注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (172.21 mM)
Ethanol 100 mg/mL (172.21 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+castor oil
10 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 580.67
化学式

C31H40N4O7

CAS号 960374-59-8
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项
免费分装抑制剂

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

相关Proteasome产品

Tags: 购买ONX-0914 (PR-957) | ONX-0914 (PR-957)供应商 | 采购ONX-0914 (PR-957) | ONX-0914 (PR-957)价格 | ONX-0914 (PR-957)生产 | 订购ONX-0914 (PR-957) | ONX-0914 (PR-957)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID